Clinical trails showed that lorlatinib had marked therapeutic effect on the ALK-positive NSCLC patients, and overcame known ALK resistance mutations, including the most common resistance mutation to the second-generation inhibitors aiming to the ALK G1202R mutant (Yang and Gong, 2019). Here, ALK is linked to non-small cell lung carcinoma.